Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Inhibrx Biosciences, Inc
Seattle Children's Hospital
Providence Health & Services
National Cancer Institute (NCI)
Providence Health & Services
R-Pharm